API's

IMPURITIES

INTERMEDIATES

METABOLITES

PHEROMONE INGREDIENTS

LINKS

 



Acarbose

Acebrophylline

Antibiotics

Anticancer Agents

Ascomycin (FK-520)

Atorvastatin

Daptomycin

Diacerein

Ecabet Sodium

Echinocandin B

Epothilone A & B

Everolimus

Geldanamycin

Glimepiride

Levocloperastine

Miglitol

Mizoribine

Mupirocin

Montelukast Sodium

Mycophenolate Mofetil

Nifuratel

Nizatidine

Orlistat

Paroxetine HCl

Pentostatin

Pimecrolimus

Pioglitazone HCl

Pitavastatin (Itavastatin)

Pneumocandin B0

Pristinamycin

Propiverine HCl

Quetiapine Fumarate

Rapamycin (Sirolimus)

Rebeccamycin

Risperidone

Rosiglitazone Maleate

Rosuvastatin

Tacrolimus (FK-506)

Teicoplanin

Vancomycin HCl

Venlafaxine HCl

Voglibose

Zonisamide

Zotarolimus


RESEARCH AND DEVELOPMENT

Active Pharmaceutical Ingredients (API's) can be produced by chemical synthesis, microbial fermentation or isolation from natural sources. Most API's are small organic molecules that are usually manufactured by using synthetic process, however, chemical processing has created major concerns for environmental protection. To some extent, it's not economical (or not possible) to produce many small or large organic molecules or biochemicals using conventional chemical process. To this end, biotechnology including microbial fermentation has been playing more and more important role in the fine chemical and pharmaceutical industry.

Most fermentation-based API's are secondary metabolites produced by micro-organisms such as fungi and actinomycetes. The micro-organisms are capable of converting inexpensive carbon sources (starch, glucose, sucrose, etc.) and nitrogen sources (soybean flour, cotton-seed flour, peptone, etc.) into expensive API's or key intermediates (such as amino acids, vitamines, antibiotics) in liquid or solid media under certain growth conditions (nutrients, temperature, PH, oxygen supply).

We are not only involved in development of synthetic process, but also paying attention to process development and optimization for production of API's and related products of small molecules using submerged fermentation technology. Current projects include process research and development for production of immuno-suppressants (Tacrolimus / FK-506, Rapamycin / Sirolimus, Everolimus, Zotarolimus, Ascomycin, Pimecrolimus, Cyclosporine, Mycophenolic Acid and Mycophenolate Mofetil), antibiotics (Vancomycin HCl, Daptomycin, Pristinamycin), anticancer agents (Epothilone A & B, Pentostatin) and antidiabetic agents (Acarbose, Miglitol, Voglibose), etc.


Copyright  © 2005  All Rights Reserved.

MOLCAN CORPORATION, Canada, Tel. 905-731-5537, Fax 905-248-3843, E-Mail: contact@molcan.com